Biologic Treatments Met Sjögren Disease Trial End Points
New therapies demonstrated clinical efficacy in phase 3 trials, potentially offering the first disease-modifying options.
Updated on Oct. 2, 2026 in Biotech
Live Poll
Do you trust that new targeted therapies will lower the financial burden for patients with chronic diseases?
Phase 3 clinical trial results have confirmed that biologics ianalumab and dazodalibep met their primary end points in treating Sjögren disease. These treatments represent a significant development in a field that currently lacks any FDA-approved disease-modifying therapies.
Why it matters
Patients with Sjögren disease currently face three times higher health care costs and greater disability than the general population, highlighting the critical need for effective interventions. This progress offers a potential path toward the first standardized disease-modifying treatment options.
Ianalumab, which received FDA breakthrough therapy designation on January 16, 2026, functions by binding to BAFF-R to deplete B cells. The 621-patient OASIZ 301 trial confirmed that dazodalibep effectively disrupts the interactions between T cells and B cells to reduce immune activation.
The players
Novartis
A global pharmaceutical company focused on innovative medicines including immunotherapies and biologics.
Amgen
A biotechnology firm that develops human therapeutics by leveraging cellular and molecular biology.
The details
Sjögren disease is a systemic autoimmune condition where the immune system attacks healthy moisture-producing glands. Ianalumab uses a mechanism that binds to the BAFF-R (B-cell activating factor receptor) to deplete B cells and inhibit their activation, while dazodalibep targets immune activation pathways to disrupt harmful cross-talk between T cells and B cells. These therapies aim to address the root autoimmune activity rather than merely managing secondary symptoms.
Timeline
January 16, 2026: FDA granted ianalumab breakthrough therapy designation.
June 8, 2026: China approved telitacicept for Sjögren disease treatment.
September 22, 2026: Amgen reported positive phase 3 results for dazodalibep.
Q4 2026: Expected completion of the OASIZ 303 trial.
The Tech Race
The global search for Sjögren disease treatments has intensified, following China's June 2026 regulatory approval of telitacicept. These new phase 3 results move ianalumab and dazodalibep into a competitive position to become the first disease-modifying treatments available in the U.S.
While these drugs are not yet available to the public, the results signal a shift toward treating the underlying autoimmune cause of Sjögren disease rather than just managing symptoms. Patients who currently face an average of 66 hours of short-term disability may eventually see a reduction in disease-related burdens as these therapies progress toward market.
The takeaway
These trial results offer the most promising evidence to date that pharmacological intervention can address the root cause of Sjögren disease. Investors and patients should monitor the completion of the OASIZ 303 trial in late 2026 for the next major milestone in the regulatory process.
What happens next
The OASIZ 303 trial is scheduled for completion in the fourth quarter of 2026, which will provide additional data on the long-term efficacy and safety profile of these therapies.
Further reading
For broader updates on immunology and therapeutic development, explore our Biotech section.
Source note: This article includes information reported by Ajmc.
Live Poll
Do you trust that new targeted therapies will lower the financial burden for patients with chronic diseases?
